Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia

Completed · Phase 1/Phase 2

Conditions studied: Beta-Thalassemia

In brief

A clinical trial designed to compare the safety and iron excretion properties of desferoxamine (DFO) and deferitrin (GT56-252), an experimental oral iron chelator.

Key facts

Study ID
NCT00069862
Run by
Genzyme, a Sanofi Company
People needed
25
Starts
2003-09-01
Expected to finish
2005-11-01
Last updated by the study team
2015-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.